Home » Stocks » QGEN

Qiagen N.V. (QGEN)

Stock Price: $48.49 USD 1.24 (2.62%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 11.09B
Revenue (ttm) 1.71B
Net Income (ttm) 163.12M
Shares Out 228.75M
EPS (ttm) 0.83
PE Ratio 58.42
Forward PE 19.31
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $48.49
Previous Close $47.25
Change ($) 1.24
Change (%) 2.62%
Day's Open 48.50
Day's Range 48.09 - 48.63
Day's Volume 535,143
52-Week Range 30.23 - 55.27

More Stats

Market Cap 11.09B
Enterprise Value 12.37B
Earnings Date (est) Feb 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 228.75M
Float 224.92M
EPS (basic) 0.70
EPS (diluted) 0.83
FCF / Share 0.76
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.71%
FCF Yield 1.62%
Payout Ratio n/a
Shares Short 4.55M
Short Ratio 4.45
Short % of Float 2.02%
Beta 0.41
PE Ratio 58.42
Forward PE 19.31
P/FCF Ratio 61.89
PS Ratio 6.48
PB Ratio 3.93
Revenue 1.71B
Operating Income 287.11M
Net Income 163.12M
Free Cash Flow 179.23M
Net Cash -1.28B
Net Cash / Share -5.61
Gross Margin 62.87%
Operating Margin 16.76%
Profit Margin 9.50%
FCF Margin 10.47%
ROA 5.05%
ROE 7.39%
ROIC 10.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (18)

Buy 8
Overweight 1
Hold 8
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

$57.59*
(18.77% upside)
Low
50.0
Current: $48.49
High
66.0
Target: 57.59
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,5261,5021,4181,3381,2811,3451,3021,2541,1701,087
Revenue Growth1.64%5.95%5.95%4.45%-4.74%3.29%3.79%7.24%7.57%-
Gross Profit998993923845827865815824750716
Operating Income-49.5327315398.8317916263.3317099.59189
Net Income-69.7710540.3980.4013011669.0713096.04144
Shares Outstanding227227228235233233225227225224
Earnings Per Share-0.310.450.170.340.560.500.310.570.430.64
EPS Growth-164.71%-50%-39.29%12%60.26%-45.36%34.04%-33.85%-
Operating Cash Flow331359287342317288259245245251
Capital Expenditures-118-110-90.04-74.47-97.68-86.56-84.42-101-84.79-76.19
Free Cash Flow213250197267220201175144160175
Cash & Equivalents7591,3741,017532427578381485276934
Total Debt1,7062,1751,7581,0671,0441,157845843577873
Net Cash / Debt-947-802-741-535-617-579-465-357-30061.48
Assets5,2365,7985,0394,3084,1934,4454,0924,1223,8343,914
Liabilities2,6993,4192,4981,7011,6961,8531,3051,3271,2011,438
Book Value2,5372,3792,5412,6072,4952,5842,7772,7842,6232,476
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Qiagen N.V.
Country Netherlands
Employees 5,300
CEO Thierry Bernard

Stock Information

Ticker Symbol QGEN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: QGEN
IPO Date June 28, 1996

Description

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels (DNA and RNA), library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc., CLIA-certified laboratories, and NuProbe Global. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.